RFX1 and cancer: Our results provide additional evidence for RFX1 as a therapeutic target for human glioblastoma and suggest that pioglitazone, rosiglitazone and WY‐14643 inhibit cancer cell behaviour of human glioblastoma cells via upregulating RFX1.